Trelegy ellipta 200-62.5-25 60S
Ended Awarded
- Contract number
- SPE2DB26FAUAS
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $5,795
Award facts
- Contract value 100% obligated
- $5,794.56 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $5,794.56 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for Trelegy Ellipta 200-62.5-25 inhalers (60-count). The award, issued on October 30, 2025, with an ultimate completion date of October 31, 2025, carries no set-aside designation, indicating the vendor competed in unrestricted federal procurement. Performance will occur at the company's facility in Conshohocken, Pennsylvania. DMS Pharmaceutical Group is headquartered in Park Ridge, Illinois, and has maintained active registration in the System for Award Management since 2001, specializing in distributing comprehensive pharmaceutical products and medical consumables to federal agencies, particularly the Department of Defense.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR. The PPV-G GEN V is a $30.3 billion acquisition strategy that authorizes DLA to issue firm fixed-price delivery orders for pharmaceutical products to support recurring medical supply needs of military healthcare facilities worldwide. DMS Pharmaceutical Group's IDC, awarded on November 13, 2025, carries a $499,999,999 ceiling value and extends through December 31, 2036, with a 30-month base period and three 30-month option periods, positioning the company as a critical pharmaceutical supplier for Department of Defense global healthcare operations.
Quick answers
Who was awarded contract SPE2DB26FAUAS?
SPE2DB26FAUAS was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 30, 2025.
How much is contract SPE2DB26FAUAS worth?
The government has obligated $5,795 on SPE2DB26FAUAS.
Is contract SPE2DB26FAUAS an order under another contract?
Yes. SPE2DB26FAUAS is a delivery order under SPE2DB24D2106, an indefinite delivery contract.
Was contract SPE2DB26FAUAS competed?
The extent of competition for SPE2DB26FAUAS was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award